About CDYMAX
CDYMAX is a Healthcare company. API manufacturing and HSE adherence in pharmaceuticals. The company has 493 employees. Its Indian entity Cdymax (India) Pharma Private Limited reported revenue of ₹285 Cr. CDYMAX offers products and services including Oncology APIs and General APIs. Its focus areas include Pharmaceuticals, API Manufacturing, Oncology APIs and General APIs.
Company details
CDYMAX is identified as a manufacturer of Active Pharmaceutical Ingredients, including Oncology and General APIs, with facilities that support specific annual capacities and maintain dedicated utilities. Adherence to Health, Safety, and Environment practices is ensured, alongside various CSR initiatives such as policy implementation and annual returns for multiple years. Operations are based in Bangalore, India, with a focus on quality and compliance, as reflected in the companys structure and projects from 2020 to 2024.
- Employees 493
- SectorsHealthcare
- Email••••••••
- Legal Name Cdymax (India) Pharma Private Limited
- Date of Incorporation 27 Oct, 1994
- Jurisdiction Bangalore, Karnataka, India
- Indian entity revenue₹285 Cr
FY 2025 · +12% YoY
- Indian entity net profit₹7.30 Cr
FY 2025 · 3% margin
- Indian entity EBITDA₹27.38 Cr
FY 2025 · 10% margin
- Employee Count493
Associated legal entities of CDYMAX
CDYMAX operates through Cdymax (India) Pharma Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2025) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Cdymax (India) Pharma Private Limited CIN U85110KA1994PTC016472 | Active | 27 Oct 1994 | Bangalore, Karnataka | ₹285 Cr | 493 | 3 | View details |
Products & Services of CDYMAX
CDYMAX offers a comprehensive portfolio of products and services, including Oncology APIs and General APIs.
Oncology Active Pharmaceutical Ingredients are produced with dedicated utilities and warehouses
General Active Pharmaceutical Ingredients are manufactured with separate lines and quality units
Board of directors of Cdymax (India) Pharma Private Limited (CDYMAX)
Cdymax (India) Pharma Private Limited is the primary company behind CDYMAX. The board of Cdymax (India) Pharma Private Limited currently have 2 directors; the longest-serving is Manorama Avinash, appointed in 2011. 8 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Manorama Avinash DIN 03457332 | Director | 07 May 2011 | 15 yrs 5 mo | Cdymax (India) Pharma Private Limited |
| Santosh Datta Naik DIN 10438286 | Director | 08 Jan 2024 | 2 yrs 9 mo | Cdymax (India) Pharma Private Limited |
Financials of CDYMAX
Figures of Cdymax (India) Pharma Private Limited, the primary company behind CDYMAX, for FY 2025. Revenue was ₹285 Cr (+12% year on year). Net profit was ₹7.30 Cr (3% margin). EBITDA was ₹27.38 Cr (10% margin). Revenue has grown at a compounded annual rate of +6% over three years and -1% over five years.
- ₹285 CrRevenue · FY 2025 · +12% YoY
- ₹7.30 CrNet profit · 3% margin
- ₹27.38 CrEBITDA · 10% margin
- ₹8.88 CrPaid-up capital
- 493Employees (provident fund records)
- +6%Revenue CAGR, 3 years
- -1%Revenue CAGR, 5 years
Balance sheet, profit and loss, cash flow and ratios of Cdymax (India) Pharma Private Limited are on its company page.
Detailed financial statements for CDYMAX
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about CDYMAX
CDYMAX has 493 employees.
The primary company behind CDYMAX, Cdymax (India) Pharma Private Limited, reported revenue of ₹285 Cr for FY 2025, up 12% year on year.
CDYMAX is identified as a manufacturer of Active Pharmaceutical Ingredients, including Oncology and General APIs, with facilities that support specific annual capacities and maintain dedicated utilities. Adherence to Health, Safety, and Environment practices is ensured, alongside various CSR initiatives such as policy implementation and annual returns for multiple years. Operations are based in Bangalore, India, with a focus on quality and compliance, as reflected in the companys structure and projects from 2020 to 2024.
CDYMAX offers Oncology APIs and General APIs.
CDYMAX operates through Cdymax (India) Pharma Private Limited.
The legal entities of CDYMAX currently have 3 directors, including Siri Surendra Bhat, Santosh Datta Naik, Manorama Avinash.